A phase I study of irinotecan and infusional cisplatin for advanced non-small-cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 4, 1997, Pages 327-332

  Mori, Kiyoshi ^a   Ohnishi, Tsukasa ^a   Yokoyama, Kohki ^b   Tominaga, Keigo ^a  

^a TOCHIGI CANCER CENTER   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Cisplatin; Continuous infusion; Irinotecan; Non small cell lung cancer; Phase I study

Indexed keywords

CISPLATIN; IRINOTECAN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG CANCER; MALE; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA;

ADULT; AGED; AGRANULOCYTOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 0031015720     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050579     Document Type: Article

References (23)

1. Bonomi P (1986) Brief overview of combination chemotherapy on non-small cell lung cancer. Semin Oncol 13 : 89
2. Bunn PA Jr (1989) The expanding role of cisplatin in the treatment of non-small-cell lung cancer. Semin Oncol 16 [Suppl. 6]: 10
3. Forastiere AA, Belliveau JF, Goren MP, Vogel WC, Posner MR, O'Leary GPJr (1988) Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum (II) in head and neck cancer patients. Cancer Res 48 : 3869
4. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10 : 16
5. Kano Y, Suzuki K, Akutsu M, Suda K, Inoue Y, Yoshida M, Sakamoto S, Miura Y (1992) Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50 : 604
6. Kanazawa F, Sugimoto Y, Minato K, Kasahara K, Bungo M, Nakagawa K, Fujiwara Y, Liu LF, Saijo N (1990) Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small-cell lung cancer: characterization and mechanism of resistance. Cancer Res 50 : 5919
7. Kasahara K, Fujiwara Y, Nishio K, Ohmori T, Sugimoto Y, Komiya K, Matsuda T, Saijo N (1991) Metallothionein content correlates with the sensitivity of human small-cell lung cancer cell lines to cisplatin. Cancer Res 51 : 3237
8. Klastersky J (1986) Therapy with cisplatin and etoposide for non-small-cell lung cancer. Semin Oncol 13 : 104
9. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T, Mutai M (1987) Anti-tumor activity of 7-ethyl-10-[4-(1-piperi-dino)-1-piperidino] carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47 : 5944
10. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K, Takada M (1992) CPT-11: a new derivative of camptothecin, for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10 : 1225
11. Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takifuji N, Nakagawa K, Kishimoto S (1992) CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10 : 1775
12. Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Takifuji N, Nakagawa K, Tamanoi M, Nitta T, Hirashima T, Negoro S, Takada M (1993) Phase I trial and pharmacologic study of irinotecan with cisplatin for advanced lung cancer. Br J Cancer 68 : 777
13. Masuda N, Fukuoka M, Kudoh S, Kusunoki Y, Matsui K, Nakagawa K, Hirashima T, Tamanoi M, Nitta T, Yana T, Negoro S, Takifuji N, Takada M (1994) Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 12 : 90
14. Matsuzaki T, Yokokura T, Mutai M, Tsuruo T (1988) Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21 : 308
15. Mori K, Saitou Y, Tominaga K (1992) Phase II study of cisplatin continuous infusion plus vindesine in the treatment of non-small-cell lung cancer. Am J Clin Oncol 15 : 344
16. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H, Taguchi T (1991) Phase I study of weekly administration of CPT-11. J Natl Cancer Inst 83 : 1164
17. Ohno R, Okada K, Masaoka T, Kuramoto A, Arima T, Yoshida Y, Ariyoshi H, Ichimaru M, Sakai Y, Oguro M, Ito Y, Morishima Y, Yokomaku S, Ota K (1990) An early phase II study of CPT-11: a new derivative of comptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol 8 : 1907
18. Rothenberg ML, Kuhn JG, Burris III HA, Nelson J, Eckardt JR, Tristan-Morales M, Hilsenbeck SG, Weiss GR, Smith LS, Rodriguez GI, Rock MK, Von Hoff DD (1993) Phase I and phamacokinetic trial of weekly CPT-11. J Clin Oncol 11 : 2194
19. Ruckdeschel JC, Finkelstein DM, Mason BA, Creech RH (1985) Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V-A randomized comparison of four cisplatin-containing regimens. J Clin Oncol 3 : 72
20. Saito Y, Mori K, Tominaga K, Yokoi K, Miyazawa N (1990) Phase II study of 5-day continuous infusion of cis-diamminedichloroplatinum (II) in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 26 : 389
21. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N (1993) Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 11 : 909
22. Shinkai T, Arioka H, Kunikane H, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Oshita F, Nishio N, Karato A, Okamoto H, Nakashima H, Ohmatsu H, Shiraishi J, Nomura N, Saijo N (1994) Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, and cisplatin in combination with fixed dose of vindesine in advanced non-small-cell lung cancer. Cancer Res 54 : 2636
23. Wittes RE (1989/1990) Grading toxicity. In: Wittes RE (ed) Manual of oncologic therapeutics. Lippincott, Philadelphia, p 628